Gender-specific care of the patient with diabetes: Review and recommendations

Gender Medicine

Volumn 3, Issue 2, 2006, Pages 131-158

  Legato, Marianne J ^a   Gelzer, Andrea ^b   Goland, Robin ^c   Ebner, Susana A ^c   Rajan, Sabitha ^d   Villagra, Victor ^e   Kosowski, Mark ^f  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CIGNA HealthCare   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d GREENWICH HOSPITAL   (United States)

^e Health and Technology Vector Inc   (United States)

^f NONE

Author keywords

biological sex; cardiovascular disease; diabetes mellitus; disease management programs; gender; insulin; peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CALCIUM; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; VITAMIN D;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; CORONARY STENT; CORRELATION ANALYSIS; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DYSLIPIDEMIA; ETHNOLOGY; EXERCISE; EXPERIENCE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; MEDLINE; MENOPAUSE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PARTICLE SIZE; PATIENT CARE; PHYSICAL ACTIVITY; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE; SEX DIFFERENCE; TRANSLUMINAL CORONARY ANGIOPLASTY; WALKING;

CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; EXERCISE; FEMALE; HUMANS; MALE; OBESITY; SEX FACTORS;

EID: 33746065672     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1550-8579(06)80202-0     Document Type: Article

References (196)

1. American Diabetes Association. Clinical practice recommendations 2004: Introduction. Diabetes Care 27 Suppl 1 (2004) S1-S2
2. Campaigne B.N., and Wishner K.L. Gender-specific health care in diabetes mellitus. J Gend Specif Med. 3 (2000) 51-58
3. Singh R., Wiegers S.E., and Goldstein B.J. Impact of gender on diabetes mellitus and its associated cardiovascular risk factors. J Gend Specif Med. 4 (2001) 28-36
4. Mosca L., Appel L.J., Benjamin E.J., et al., American Heart Association, American College of Cardiology, American College of Nurse Practitioners, American College of Obstetricians and Gynecologists, American College of Physicians, American Medical Women's Association, Association of Black Cardiologists, Centers for Disease Control and Prevention, National Heart, Lung, and Blood Institute, National Institutes of Health, Office of Research on Women's Health, Society of Thoracic Surgeons, World Heart Federation. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol. 43 (2004) 900-921
5. Nathan D.M., Lachin J., Cleary P., et al., Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 348 (2003) 2294-2303
6. (Suppl). Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. II. Mortality results. Diabetes 19 (1970) 789-830
7. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulindependent diabetes mellitus: The Finnish studies. Ann Intern Med. 124 (1996) 127-130
8. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48 (1999) 937-942
9. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353 (1999) 617-622
10. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2 (2000) B21-B29
11. Babaya N., Nakayama M., and Eisenbarth G.S. The stages of type lA diabetes. Ann N Y Acad Sci. 1051 (2005) 194-204
12. Apridonidze T., Essah P.A., Iuorno M.J., and Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrlnol Metab. 90 (2005) 1929-1935
13. Rhodes C.J. Type 2 diabetes-a matter of beta-cell life and death?. Science 307 (2005) 380-384
14. Lowell B.B., and Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005) 384-387
15. Genuth S., Alberti K.G., Bennett P., et al., Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
16. [published correction appears in Diabetes Care. 2005;28:990]. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 28 Suppl 1 (2005) S4-S36
17. Meigs J.B., Nathan D.M., D'Agostino Sr. R.B., Wilson P.W., and Framingham Offspring Study. Fasting and the postchallenge glycemia and cardiovascu lar disease risk: The Framingham Offspring Study. Diabetes Care 25 (2002) 1845-1850
18. Tesfaye S., Chaturvedi N., Eaton S.E., et al., EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 352 (2005) 341-350
19. Witte D.R., Tesfaye S., Chaturvedi N., et al., EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neu ropathy in type 1 diabetes mellitus. Diabetologia 48 (2005) 164-171
20. Lehtinen J.M., Uusitupa M., Siitonen O., and Pyorala K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 38 (1989) 1307-1313
21. Steel J.M., Young R.J., Lloyd G.G., and Clarke B.E. Clinically apparent eating disorders in young diabetic women: Associations with painful neuropathy and other complications. BMJ (Clin Res Ed) 294 (1987) 859-862
22. Seaquist E.R., Goetz F.C., Rich S., and Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 320 (1989) 1161-1165
23. Krolewski A.S., Canessa M., Warram J.H., et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318 (1988) 140-145
24. Freire M.B., Ji L., Onuma T., et al. Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension 31 (1998) 896-899
25. In: Skyler J.S. (Ed). Medical Management of Type 1 Diabetes. 3rd ed (1998), ADA, Alexandria, Va 16
26. Williams A.J., Bingley P.J., Moore W.P., Gale E.A., and ENDIT Screening Group (European Nicotinamide Diabetes Intervention Trial). Islet autoantibodies, nationality and gender: A multinational screening study in first-degree relatives of patients with type I diabetes. Diabetologia 45 (2002) 217-223
27. Gale E.A., and Gillespie K.M. Diabetes and gender. Diabetologia 44 (2001) 3-15
28. Mokdad A.H., Ford E.S., Bowman B.A., et al. The continuing increase of diabetes in the US. Diabetes Care 24 (2001) 412
29. Boyle J.P., Honeycutt A.A., Narayan K.M., et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the US. Diabetes Care 24 (2001) 1936-1940
30. Centers for Disease Control. Statistics: 1999 Surveillance Report. Available at: http://www.cdc.gov/ diabetes/statistics/survl99/index.htm.
31. Harvey J.N., Craney L., and Kelly D. Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: Comparison of record linkage with capture-recapture analysis. J Epidemiol Community Health 56 (2002) 18-23
32. Cockram C.S. The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 6 (2000) 43-52
33. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
34. Yajnik C.S. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J Nutr 134 (2004) 205-210
35. Pradeepa R., Deepa R., and Mohan V. Epidemiology of diabetes in India-current perspective and future projections. J Indian Med Assoc 100 (2002) 144-148
36. Pan X.R., Yang W.Y., Li G.W., Liu J., and National Diabetes Prevention and Control Cooperative Group. Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 20 (1997) 1664-1669
37. Kaufman F.R. Type 2 diabetes in children and youth. Endocrinol Metab Clin North Am 34 (2005) 659-676
38. Kaufman F.R. Type 2 diabetes in children and youth. Endocrinol Metab Clin North Am 34 (2005) ix-x
39. Warram J.H., Martin B.C., Krolewski A.S., et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113 (1990) 909-915
40. Petersen K.F., Dufour S., Befroy D., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350 (2004) 664-671
41. [in Swedish]. Luft R., and Luthman H. Physiopathology of mitochondria. From Luft's disease to aging and diabetes. Lakartidningen 90 (1993) 2770-2775
42. Wisloff U., Najjar S.M., Ellingsen O., et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science 307 (2005) 418-420
43. Hales C.N., Barker D.J., Clark P.M., et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303 (1991) 1019-1022
44. Rich-Edwards J.W., Colditz G.A., Sampfer M.J., et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med 130 (1999) 278-284
45. Forsen T., Eriksson J., Tuomilehto J., et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 133 (2000) 176-182
46. Eriksson J.G., Forsen T., Tuomilehto J., et al. Early adiposity rebound in childhood and risk of type 2 diabetes in adult life. Diabetologia 46 (2003) 190-194
47. Bhargava S.K., Sachdev H.S., Fall C.H., et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 350 (2004) 865-875
48. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
49. discussion. Friedman J.M. The function of leptin in nutrition, weight, and physiology. Nutr Rev 60 (2002) S1-S14
50. Friedman J.M. The function of leptin in nutrition, weight, and physiology. Nutr Rev 60 (2002) S68-S87
51. Bergman R.N., and Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11 (2000) 351-356
52. Schwartz M.W., and Porte Jr. D. Diabetes, obesity, and the brain. Science 307 (2005) 375-379
53. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122 (1995) 481-486
54. Hu F.B., Willett W.C., Li T., et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 351 (2004) 2694-2703
55. Villareal D.T., and Holloszy J.O. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 292 (2004) 2243-2248
56. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA 276 (1996) 241-246
57. Hu F.B., Stampfer M.J., Solomon C., et al. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 134 (2001) 96-105
58. Lee I.M., Rexrode K.M., Cook N.R., et al. Physical activity and coronary heart disease in women: Is "no pain, no gain" passe?. JAMA 285 (2001) 1447-1454
59. Gregg E.W., Cauley J.A., Stone K., et al., Study of Osteoporotic Fractures Research Group. Relationships of changes in physical activity and mortality among older women. JAMA 289 (2003) 2379-2386
60. Wei M., Gibbons L.W., Kampert J.B., et al. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 132 (2000) 605-611
61. Manson J.E., Colditz G.A., Stampfer MJ., et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151 (1991) 1141-1147
62. Juutilainen A., Kortelainen S., Lehto S., et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 27 (2004) 2898-2904
63. [published correction appears in JAMA. 1989;261:1884]. Abbott R.D., Donahue R.P., Kannel W.B., and Wilson P.W. The impact of diabetes on survival following myocardial infarction in men vs women: The Framingham Study. JAMA 260 (1988) 3456-3460
64. Hu G., Jousilahti P., Qiao Q., et al. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or with out history of myocardial infarction. Diabetologia 48 (2005) 856-861
65. Hu G., and DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 46 (2003) 608-617
66. Hu G., Jousilahti P., Qiao Q., et al. The genderspecific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol 45 (2005) 1413-1418
67. Juutilainen A., Lehto S., Ronnemaa T., et al. Type 2 diabetes as a "coronary heart disease equivalent": An 18-year prospective population-based study in Finnish subjects. Diabetes Care 28 (2005) 2901-2907
68. Steinberg H.O., Paradisi G., Cronin J., et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101 (2000) 2040-2046
69. Chan P., and Pan W.H. Coagulation activation in type 2 diabetes mellitus: The higher coronary risk of female diabetic patients. Diabet Med 12 (1995) 504-507
70. Carr M.E. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 15 (2001) 44-54
71. Gum P.A., Thamilarasan M., Watanabe J., et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 286 (2001) 1187-1194
72. Hu F.B., Manson J.E., Stampfer M.J., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345 (2001) 790-797
73. Haapanen N., Miilunpalo S., Vuori I., et al. Association of leisure time physical activity with the risk of coronary heart disease, hypertension and diabetes in middle-aged men and women. Int J Epidemiol 26 (1997) 739-747
74. Manson J.E., Rimm E.B., Stampfer M.J., et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 338 (1991) 774-778
75. Griffith L.S., and Lustman P.J. Depression in women with diabetes. Diabetes Spectrum 10 (1997) 216-223
76. Anderson R.J., Freedland K.E., Clouse R.E., and Lustman P.J. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care 24 (2001) 1069-1078
77. Goodnick P.J., Henry J.H., and Buki V.M. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 56 (1995) 128-136
78. Levine M.D., and Marcus M.D. Women, diabetes and disordered eating. Diabetes Spectrum 10 (1997) 191-194
79. Rydall A.C., Rodin G.M., Olmsted M.P., et al. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N Engl J Med 336 (1997) 1849-1854
80. [published correction appears in Diabetes Care. 1998;21:1382]. Ahmed M.L., Connors M.H., Drayer N.M., et al. Pubertal growth in IDDM is determined by HbAlc levels, sex, and bone age. Diabetes Care 21 (1998) 831-835
81. Mankhey R.W., Bhatti F., and Maric C. 17-Beta-estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 288 (2005) F399-F405
82. Wells C.C., Riazi S., Mankhey R.W., et al. Diabetic nephropathy is associated with decreased circulating estradiol levels and imbalance in the ex pression of renal estrogen receptors. Gend Med 2 (2005) 227-237
83. Hypertension in Diabetes Study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11 (1993) 309-317
84. Grundy S.M., Howard B., Smith Jr. S., et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive summary: Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105 (2002) 2231-2239
85. Howard B.V., Cowan L.D., Go O., et al., Strong Heart Study. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 21 (1998) 1258-1265
86. Whitsel E.A., Boyko E.J., and Siscovick D.S. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: A meta-analysis. Diabetes Care 23 (2000) 241-247
87. Olson J.C., Edmundowicz D., Becker D.J., et al. Coronary calcium in adults with type 1 diabetes: A stronger correlate of clinical coronary artery disease in men than in women. Diabetes 49 (2000) 1571-1578
88. Krakauer J.C., McKenna M.J., Buderer N.F., et al. Bone loss and bone turnover in diabetes. Diabetes 44 (1995) 775-782
89. [in Japanese]. Kumeda Y., Inaba M., and Nishizawa Y. Secondary osteoporosis and its treatment-diabetes mellitus. Nippon Rinsho 56 (1998) 1579-1586
90. van Daele P.L., Stolk R.P., Burger H., et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 122 (1995) 409-414
91. Koro C.E., Fedder D.O., L'Italien G.J., et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study. BMJ 325 (2002) 243
92. Jin H., Meyer J.M., and Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry 14 (2002) 59-64
93. [published correction appears in N Engl J Med. 1995;333: 1435]. Franks S. Polycystic ovary syndrome. N Engl j Med 333 (1995) 853-861
94. Dunaif A. Insulin resistance and ovarian dysfunction. In: Moller D.E. (Ed). Insulin Resistance (1993), John Wiley, New York, NY 301-325
95. Dunaif A., Scott D., Finegood D., et al. The insulinsensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycys tic ovary syndrome. J Clin Endocrinol Metab 81 (1996) 3299-3306
96. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after firsttrimester exposure to ACE inhibitors. N Engl J Med 354 (2006) 2443-2451
97. Briggs G.G. Drug effects on the fetus and breastfed infant. Clin Obstet Gynecol 45 (2002) 6-21
98. Tabacova S., Little R., Tsong Y., et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 12 (2003) 633-646
99. Clark Jr. C.M., Qiu C., Amerman B., et al. Gestational diabetes: Should it be added to the syndrome of insulin resistance?. Diabetes Care 20 (1997) 867-871
100. de Veciana M., Major C.A., Morgan M.A., et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333 (1995) 1237-1241
101. Dabelea D., Hanson R.L., Bennett P.H., et al. Increasing prevalence of type II diabetes in American Indian children. Diabetologia 41 (1998) 904-910
102. Dabelea D., Hanson R.L., Lindsay R.S., et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: A study of discordant sibships. Diabetes 49 (2000) 2208-2211
103. Lunt H. Women and diabetes. Diabet Med 13 (1996) 1009-1016
104. Petersen K.R., Skouby S.O., Sidelmann J., et al. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent dia betes mellitus. Am J Obstet Gynecol 171 (1994) 400-405
105. Kaplan R.C., Heckbert S.R., Weiss N.S., et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 21 (1998) 1117-1121
106. Andersson B., Mattsson L.A., Hahn L., et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeosta sis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82 (1997) 638-643
107. Manson J.E., Rimm E.B., Colditz G.A., et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non insulin-dependent diabetes mellitus. Ann Epidemiol 2 (1992) 665-673
108. Margolis K.L., Bonds D.E., Rodabough R.J., et al., Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the inci dence of diabetes in postmenopausal women: Results from the Women's Health Initiative Hormonal Trial. Diabetologia 47 (2004) 1175-1187
109. Kanaya A.M., Herrington D., Vittinghoff E., et al., Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
110. Ferrara A., Karter A.J., Ackerson L.M., et al. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 24 (2001) 1144-1150
111. Friday K.E., Dong C., and Fontenot R.U. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 48-52
112. Barrett-Connor E., Giardina E.G., Gitt A.K., et al. Women and heart disease: The role of diabetes and hyperglycemia. Arch Intern Med 164 (2004) 934-942
113. Kannel W.B., and Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 155 (1995) 57-61
114. Roberts B.H. Gender-specific aspects of the experience of coronary artery disease. In: Legato M.J. (Ed). Principles of Gender-Specific Medicine Vol 1 (2004), Elsevier Academic Press, San Diego, Calif 215-223
115. Hu F.B., Stampfer M.J., Haffner S.M., et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002) 1129-1134
116. Fang Z.Y., Prins J.B., and Marwick T.H. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 25 (2004) 543-567
117. Gu K., Cowie C.C., and Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999) 1291-1297
118. Kaseta J.R., Skafar D.F., Ram J.L., et al. Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab 84 (1999) 1835-1838
119. Kannel W.B., and McGee D.L. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 59 (1979) 8-13
120. Kanaya A.M., Grady D., and Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: A meta-analysis. Arch Intern Med 162 (2002) 1737-1745
121. Orchard T.J. The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 28 (1996) 323-333
122. Lee W.L., Cheung A.M., Cape D., and Zinman B. Impact of diabetes on coronary artery disease in women and men: A meta-analysis of prospective studies. Diabetes Care 23 (2000) 962-968
123. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic sub jects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
124. Natarajan S., Liao Y., Cao G., et al. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 163 (2003) 1735-1740
125. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
126. Koerbel G., and Korytkowski M. Coronary heart disease in women with diabetes. Diabetes Spectrum 16 (2003) 148-153
127. The Diabetes Epidemiology Research International (DERI) Study. Sex differences in the mortality associated with insulin-dependent diabetes mellitus in four countries. Am J Epidemiol 133 (1991) 577-584
128. Gregg E.W., Mangione C.M., Cauley J.A., et al., Study of Osteoporotic Fractures Research Group. Diabetes and the incidence of function al disability in older women. Diabetes Care 25 (2002) 61-67
129. Tavani A., Bertuzzi M., Gallus S., et al. Diabetes mellitus as a contributor to the risk of acute myocardial infarction. J Clin Epidemiol 55 (2002) 1082-1087
130. Hu F.B., Stampfer M.J., Solomon C.G., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 Years of follow-up. Arch Intern Med 161 (2001) 1717-1723
131. Legato M.J. Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: Implications for therapy. Am J Cardiol 86 (2000) 15L-18L
132. Mosca L., Manson J.E., Sutherland S.E., et al. Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association Writing Group. Circulation 96 (1997) 2468-2482
133. Goldschmid M.G., Barrett-Connor E., Edelstein S.L., et al. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation 89 (1994) 991-997
134. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20 (1997) 1683-1687
135. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
136. Walden C.E., Knopp R.H., Wahl P.W., et al. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 311 (1984) 953-959
137. Haffner S.M., Mykkanen L., Stern M.P., et al. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 17 (1994) 1164-1171
138. Flegal K.M., Carroll M.D., Kuczmarski R.J., and Johnson C.L. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 22 (1998) 39-47
139. Manson J.E., Hu F.B., Rich-Edwards J.W., et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 341 (1999) 650-658
140. Bassuk S.S., and Manson J.A. Gender and its impact on risk factors for cardiovascular disease. In: Legato M.J. (Ed). Principles of Gender-Specific Medicine Vol 1 (2004), Elsevier Academic Press, San Diego, Calif 193-214
141. Hanson R.L., Narayan K.M., McCance D.R., et al. Rate of weight gain, weight fluctuation, and incidence of NIDDM. Diabetes 44 (1995) 261-266
142. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
143. Resnick H.E., and Howard B.V. Diabetes and cardiovascular disease. Annu Rev Med 53 (2002) 245-267
144. Franklin S.S. Definition and epidemiology of hypertensive cardiovascular disease in women: The size of the problem. J Hypertens Suppl 20 (2002) S3-S5
145. Elveback L.R., Connolly D.C., and Melton III L.J. Coronary heart disease in residents of Rochester, Minnesota. VII. Incidence, 1950 through 1982. Mayo Clin Proc 61 (1986) 896-900
146. Glynn R.J., L'Italien G.J., Sesso H.D., et al. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 39 (2002) 105-110
147. Giugliano D., Ceriello A., and Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19 (1996) 257-267
148. Witztum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88 (1991) 1785-1792
149. Marra G., Cotroneo P., Pitocco D., et al. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: A case for gender difference. Diabetes Care 25 (2002) 370-375
150. Evans R.W., and Orchard T.J. Oxidized lipids in insulin-dependent diabetes mellitus: A sex-diabetes interaction?. Metabolism 43 (1994) 1196-1200
151. Peiris A.N., Aiman E.J., Drucker W.D., and Kissebah A.H. The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandro genic women. J Clin Endocrinol Metab 68 (1989) 715-720
152. Newton K.M., LaCroix A.Z., Heckbert S.R., et al. Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diabetes Care 26 (2003) 2810-2816
153. Barrett-Connor E. Diabetes and heart disease. Diabetes Care 26 (2003) 2947-2958
154. Giardina E.G. Heart disease in women. Int J Fertil Womens Med 45 (2000) 350-357
155. Steingart R.M., Packer M., Hamm P., et al., Survival and Ventricular Enlargement Investigators. Sex differences in the management of coronary artery disease. N Engl J Med 325 (1991) 226-230
156. Hulley S., Grady D., Bush T., et al., Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
157. Fonarow G.C., French W.J., Parsons L.S., et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 103 (2001) 38-44
158. Wexler D.J., Grant R.W., Meigs J.B., et al. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28 (2005) 514-520
159. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 41 (2003) 1529-1538
160. Walsh J.M., and Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
161. Ridker P.M., Cannon C.P., Morrow D., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
162. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al., Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
163. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
164. Ridker P.M., Bassuk S.S., and Toth P.P. C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Curr Atheroscler Rep 5 (2003) 341-349
165. Ehrenstein M.R., Jury E.C., and Mauri C. Statins for atherosclerosis-as good as it gets?. N Engl J Med 352 (2005) 73-75
166. Gilbert J., Raboud J., and Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 27 (2004) 990-994
167. Watanabe C.T., Maynard C., and Ritchie J.L. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol 88 (2001) 848-852
168. Jacobs A.K., Johnston J.M., Haviland A., et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: A report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol 39 (2002) 1608-1614
169. Mehilli J., Kastrati A., Bollwein H., et al. Gender and restenosis after coronary artery stenting. Eur Heart J 24 (2003) 1523-1530
170. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRollmUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
171. Flaherty J.D., and Davidson C.J. Diabetes and coronary revascularization. JAMA 293 (2005) 1501-1508
172. Furnary A.P., Gao G., Grunkemeier G.L., et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125 (2003) 1007-1021
173. Huang E.S., Meigs J.B., and Singer D.E. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111 (2001) 633-642
174. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
175. Granger C.B., Califf R.M., Young S., et al., Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 21 (1993) 920-925
176. Hirsh I.B. Insulin analogues. N Engl J Med 352 (2005) 174-183
177. Buchbinder A., Miodovnik M., Khoury J., and Sibai B.M. Is the use of insulin lispro safe in pregnancy?. J Matern Fetal Neonatal Med 11 (2002) 232-237
178. Garg S.K., Frias J.P., Anil S., et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: Glycemic control and maternal and fetal outcomes. Endocr Pract 9 (2003) 187-193
179. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
180. Song S.H., and Brown P.M. Coronary heart disease risk assessment in diabetes mellitus: Comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 21 (2004) 238-245
181. Colagiuri S., Cull C.A., Holman R.R., and UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK Prospective Diabetes Study 61. Diabetes Care 25 (2002) 1410-1417
182. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
183. Dahlof B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
184. Dornhorst A., Powell S.H., and Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics with out alteration of insulin secretion. Lancet 1 (1985) 123-126
185. Holzgreve H., Nakov R., Beck K., and Janka H.U. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 16 (2003) 381-386
186. Bakris G.L., Fonseca V., Katholi R.E., et al., GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292 (2004) 2227-2236
187. Villagra V. Strategies to control costs and quality: A focus on outcomes research for disease management. Med Care 42 Suppl 4 (2004) 11124-11130
188. Faxon D.P., Schwamm L.H., Pasternak R.C., et al., American Heart Association's Expert Panel on Disease Management. Improving qual ity of care through disease management: Principles and recommendations from the American Heart Association's Expert Panel on Disease Management. Circulation 109 (2004) 2651-2654
189. Sidorov J., Shull R., Tomcavage J., et al. Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care 25 (2002) 684-689
190. Available at. Department of Health and Human Services. Centers for Medicare & Medicaid Services. Medicare health support overview (January 23, 2006). http://www.cms.hhs.gov/CCIP/downloads/MHSOverview012306.pdf
191. National Committee for Quality Assurance. Disease management accreditation & certification status list. Available at: http://www.ncqa. org/programs/accreditation/DM/dmaccredstatus.htm.
192. April. Joint Commission on Accreditation of Healthcare Organizations. The Joint Commission: Assessing the quality of care in disease manage ment. Available at (2003). http://www.joint.ommission.org/NR/rdonlyres/03CA5204D19D
193. URAC. Disease management accreditation program overview. Available at: http://www.urac.org/prog-accred DM-po.asp?navid=accreditation pagename=prog-accred DM.
194. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
195. Grant R.W., Pirraglia P.A., Meigs J.B., and Singer D.E. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 164 (2004) 1134-1139
196. Rothman R.L., DeWalt D.A., Malone R., et al. Influence of patient literacy on the effectiveness of a primary care-based diabetes disease management program. JAMA 292 (2004) 1711-1716